Home PipelineMGD024 (CD123 × CD3)

Background

MGD024 is an investigational, next-generation, bispecific CD123 × CD3 DART® molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia (AML). MGD024 was designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life.

Clinical Development

In December 2021, we presented preclinical MGD024 data at the American Society of Hematology (ASH) Annual Meeting that showed the potential for anti-tumor activity from the combination of MGD024 with standard of care agents used to treat AML. MacroGenics plans to initiate a Phase 1 study of MG024 in patients with hematologic malignancies in mid-2022.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close